ZA201701526B - Methods of treating depression using nmda modulators - Google Patents
Methods of treating depression using nmda modulatorsInfo
- Publication number
- ZA201701526B ZA201701526B ZA2017/01526A ZA201701526A ZA201701526B ZA 201701526 B ZA201701526 B ZA 201701526B ZA 2017/01526 A ZA2017/01526 A ZA 2017/01526A ZA 201701526 A ZA201701526 A ZA 201701526A ZA 201701526 B ZA201701526 B ZA 201701526B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- treating depression
- nmda modulators
- nmda
- modulators
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037374P | 2014-08-14 | 2014-08-14 | |
| PCT/US2015/045071 WO2016025721A1 (en) | 2014-08-14 | 2015-08-13 | Methods of treating depression using nmda modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201701526B true ZA201701526B (en) | 2018-05-30 |
Family
ID=55304631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/01526A ZA201701526B (en) | 2014-08-14 | 2017-03-01 | Methods of treating depression using nmda modulators |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20170296616A1 (enExample) |
| EP (1) | EP3180015A4 (enExample) |
| JP (2) | JP2017524721A (enExample) |
| KR (1) | KR20170040351A (enExample) |
| CN (1) | CN106659763A (enExample) |
| AU (2) | AU2015301650A1 (enExample) |
| BR (1) | BR112017002930A2 (enExample) |
| CA (1) | CA2957937A1 (enExample) |
| CL (1) | CL2017000378A1 (enExample) |
| CO (1) | CO2017002356A2 (enExample) |
| IL (1) | IL250557A0 (enExample) |
| MX (1) | MX2017002052A (enExample) |
| PH (1) | PH12017500275A1 (enExample) |
| RU (1) | RU2017107033A (enExample) |
| SG (2) | SG10201810016XA (enExample) |
| UA (1) | UA123623C2 (enExample) |
| WO (1) | WO2016025721A1 (enExample) |
| ZA (1) | ZA201701526B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3362080A1 (en) * | 2015-10-16 | 2018-08-22 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| US11358935B2 (en) | 2016-11-28 | 2022-06-14 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of lanicemine and their method of use |
| WO2018234568A2 (en) * | 2017-06-23 | 2018-12-27 | Develco Pharma Schweiz Ag | Hydroxynorketamine for the use in the treatment of depression |
| WO2019094676A1 (en) * | 2017-11-10 | 2019-05-16 | Naurex Inc. | Methods of administration of nmda receptor agonists |
| EP3720464A1 (en) * | 2017-12-05 | 2020-10-14 | Naurex Inc. | Nmda receptor modulators (rapastinel) combination for use in combined treatment (sleep and cns disorder) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| HRP20140784T1 (hr) * | 2009-10-05 | 2014-10-10 | Northwestern University | Glyx-13 za uporabu u postupku tretiranja refraktornih depresija |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
-
2015
- 2015-08-13 RU RU2017107033A patent/RU2017107033A/ru not_active Application Discontinuation
- 2015-08-13 AU AU2015301650A patent/AU2015301650A1/en not_active Abandoned
- 2015-08-13 MX MX2017002052A patent/MX2017002052A/es unknown
- 2015-08-13 SG SG10201810016XA patent/SG10201810016XA/en unknown
- 2015-08-13 CN CN201580043626.3A patent/CN106659763A/zh active Pending
- 2015-08-13 JP JP2017507973A patent/JP2017524721A/ja active Pending
- 2015-08-13 UA UAA201702145A patent/UA123623C2/uk unknown
- 2015-08-13 KR KR1020177006761A patent/KR20170040351A/ko not_active Ceased
- 2015-08-13 EP EP15832514.2A patent/EP3180015A4/en not_active Withdrawn
- 2015-08-13 BR BR112017002930A patent/BR112017002930A2/pt not_active IP Right Cessation
- 2015-08-13 WO PCT/US2015/045071 patent/WO2016025721A1/en not_active Ceased
- 2015-08-13 CA CA2957937A patent/CA2957937A1/en not_active Abandoned
- 2015-08-13 US US15/503,840 patent/US20170296616A1/en not_active Abandoned
- 2015-08-13 SG SG11201701134XA patent/SG11201701134XA/en unknown
-
2017
- 2017-02-12 IL IL250557A patent/IL250557A0/en unknown
- 2017-02-14 CL CL2017000378A patent/CL2017000378A1/es unknown
- 2017-02-14 PH PH12017500275A patent/PH12017500275A1/en unknown
- 2017-03-01 ZA ZA2017/01526A patent/ZA201701526B/en unknown
- 2017-03-10 CO CONC2017/0002356A patent/CO2017002356A2/es unknown
-
2020
- 2020-04-23 JP JP2020076468A patent/JP2020128391A/ja active Pending
- 2020-05-15 AU AU2020203165A patent/AU2020203165A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170040351A (ko) | 2017-04-12 |
| EP3180015A4 (en) | 2018-02-14 |
| EP3180015A1 (en) | 2017-06-21 |
| WO2016025721A1 (en) | 2016-02-18 |
| AU2015301650A1 (en) | 2017-03-23 |
| CA2957937A1 (en) | 2016-02-18 |
| IL250557A0 (en) | 2017-03-30 |
| BR112017002930A2 (pt) | 2017-12-05 |
| SG10201810016XA (en) | 2018-12-28 |
| CO2017002356A2 (es) | 2017-06-09 |
| RU2017107033A3 (enExample) | 2019-02-12 |
| US20170296616A1 (en) | 2017-10-19 |
| MX2017002052A (es) | 2018-08-15 |
| JP2020128391A (ja) | 2020-08-27 |
| CN106659763A (zh) | 2017-05-10 |
| PH12017500275A1 (en) | 2017-07-03 |
| RU2017107033A (ru) | 2018-09-14 |
| SG11201701134XA (en) | 2017-03-30 |
| JP2017524721A (ja) | 2017-08-31 |
| AU2020203165A1 (en) | 2020-06-04 |
| UA123623C2 (uk) | 2021-05-05 |
| CL2017000378A1 (es) | 2017-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286669A (en) | Compounds and methods for modulating tmprss6 expression | |
| IL279627A (en) | A method for treating depression | |
| IL259421B (en) | ror - gamma modulators | |
| ZA201802663B (en) | Modulators of kras expression | |
| SG11201700070QA (en) | Modulators of toll-like receptors for the treatment of hiv | |
| IL264482A (en) | Spiro-lactam nmda modulators and methods of their use | |
| EP3116851A4 (en) | Analogs of fexaramine and methods of making and using | |
| IL247847B (en) | ror gamma modulator and their use | |
| ZA201605332B (en) | Trpa1 modulators | |
| PL3303293T3 (pl) | Modulatory ROR-gamma | |
| PL3303291T3 (pl) | Modulatory ROR-gamma | |
| PL3303290T3 (pl) | Modulatory ROR-gamma | |
| ZA201701526B (en) | Methods of treating depression using nmda modulators | |
| PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORγ) | |
| GB201416832D0 (en) | Methods of treatment | |
| IL249434B (en) | Use of active negative modulators of erythropoietin for treatment | |
| EP3171941A4 (en) | N-methyl-d-aspartate receptor modulators and methods of making and using same | |
| EP3105471A4 (en) | Apparatus for use of chain | |
| IL247234A0 (en) | Caspase-6 modulators | |
| SG11201607445QA (en) | Methods of modulating wars2 | |
| AU362355S (en) | Surface-treatment apparatus | |
| GB201413982D0 (en) | Bridge distribution apparatus | |
| HK1238136A1 (en) | Methods of treating depression using nmda modulators | |
| GB2524547B (en) | Delta Sigma modulators | |
| GB201400215D0 (en) | Modulators |